EP 1292297 A1 20030319 - PHARMACEUTICAL COMBINATION OF BICALUTAMIDE AND ANASTROZOLE FOR PROVIDING AN ANTI-ANDROGENIC EFFECT AND AROMATASE INHIBITION
Title (en)
PHARMACEUTICAL COMBINATION OF BICALUTAMIDE AND ANASTROZOLE FOR PROVIDING AN ANTI-ANDROGENIC EFFECT AND AROMATASE INHIBITION
Title (de)
PHARMAZEUTISCHE ZUSAMMENSTELLUNGEN AUS BICALUTAMID UND ANASTROZOL ZUR ERREICHUNG EINES ANTIANDROGENEN EFFEKTS UND ZUR AROMATASEHEMMUNG
Title (fr)
COMBINAISON PHARMACEUTIQUE DE BICALUTAMIDE ET D'ANASTROZOLE PERMETTANT D'OBTENIR UN EFFET ANTI-ANDROGENE ET L'INHIBITION DE L'AROMATASE
Publication
Application
Priority
- GB 0012293 A 20000523
- SE 0101163 W 20010522
Abstract (en)
[origin: WO0189516A1] The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising 4'-cyano-<i> alpha '</i>, alpha ', alpha '-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropriono-<i>m</i>-toluidide (compound I) and anastrozole. The invention also relates to a method of providing an anti-anrogenic effect and aromatase inhibition in a patient, wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens.
IPC 1-7
IPC 8 full level
A61K 31/275 (2006.01); A61K 31/277 (2006.01); A61K 31/4196 (2006.01); A61P 5/28 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01)
CPC (source: EP)
A61K 31/277 (2013.01); A61K 31/4196 (2013.01); A61P 5/28 (2017.12); A61P 35/00 (2017.12); A61P 43/00 (2017.12)
Citation (search report)
See references of WO 0189516A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 0189516 A1 20011129; AU 6283401 A 20011203; EP 1292297 A1 20030319; GB 0012293 D0 20000712; JP 2003534279 A 20031118
DOCDB simple family (application)
SE 0101163 W 20010522; AU 6283401 A 20010522; EP 01937066 A 20010522; GB 0012293 A 20000523; JP 2001585760 A 20010522